2014

CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001

LUND, Sweden, November 27, 2013 /PRNewswire/ --

CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001. The Orphan Drug Designation has been granted for CMC-001 for use as a targeted contrast agent for diagnostic MRI for detection and localization of focal liver lesions in patients where gadolinium-based contrast agents are contraindicated or cannot be administered.

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to novel drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the U.S. The designation confers special incentives to the drug developer, including tax credits towards the cost of clinical trials, prescription drug user fee waivers and may entitle a period of seven years U.S market exclusivity upon FDA approval.

Magnus Corfitzen, Chairman of CMC Contrast AB "The diagnostic benefits of enhanced MRI liver imaging in detecting and localizing focal liver lesions are well established. However, a small subset of patient groups cannot undergo enhanced liver MRI procedures due to the risks of severe side effects associated with currently used gadolinium based contrast agents. For these patients, including patients with severe chronic renal insufficiency, important diagnostic information may be missed due to lack of contrast enhanced MRI. CMC-001 will allow radiologists to obtain the best possible diagnostic information in these subsets of patients, enabling clinicians to select the optimal treatment option for these patients. This is not possible today as clinicians only have access to data from an unenhanced imaging procedure on which they will base their disease management decisions for these patients"

The FDA decision to grant the Orphan Drug Designation to CMC-001 is an important milestone for CMC Contrast AB.  The company is now planning a pivotal phase III clinical program which in conjunction with the completed phase I and II clinical studies should enable CMC-001 to obtain regulatory approval and marketing authorization in the US. CMC-001 will then become available to patients in need of a liver MRI procedure for whom gadolinium based contrast agents are contraindicated or cannot be administered.

About CMC Contrast

CMC Contrast AB is a privately owned drug development company that specializes in developing targeted contrast agents for Magnetic Resonance Imaging (MRI). CMC Contrast AB's product CMC-001 is the world's first oral contrast agent for MRI of the liver. CMC-001 is an oral manganese-based contrast agent which enables safe liver enhancement in MRI, in patients for whom gadolinium based contrast agents are contraindicated or cannot be administered. A liver MRI scan is a specialized radiology procedure used to examine the liver to identify certain conditions or diseases which can be malignant cancerous or benign lesions.

CMC Contrast is based in Lund, Sweden, and funded by prominent VC investors including Sunstone Capital, Industrifonden and Øresund Healthcare. http://www.cmccontrast.com

Contact
Magnus Corfitzen
Chairman, CMC Contrast AB
Email: moc@cmccontrast.com
Tel: +45-40-80-48-63


SOURCE CMC Contrast




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.